liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial
Uppsala Univ Hosp, Sweden.
Uppsala Univ Hosp, Sweden.
Skane Univ Hosp, Sweden.
Heidelberg Univ, Germany.
Show others and affiliations
2024 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 38, no 4, p. 781-787Article in journal (Refereed) Published
Abstract [en]

Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for >= one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for >= 1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2(nd) stop. After a median follow-up of 27 months from 2(nd) stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR4 within a median of 3 months from TKI re-initiation. In summary, we show that a 2(nd) TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.

Place, publisher, year, edition, pages
Springer Nature, 2024. Vol. 38, no 4, p. 781-787
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-202359DOI: 10.1038/s41375-024-02145-6ISI: 001188070700001PubMedID: 38278960Scopus ID: 2-s2.0-85183379737OAI: oai:DiVA.org:liu-202359DiVA, id: diva2:1851060
Note

Funding Agencies|Uppsala University

Available from: 2024-04-12 Created: 2024-04-12 Last updated: 2025-02-25

Open Access in DiVA

fulltext(1064 kB)53 downloads
File information
File name FULLTEXT01.pdfFile size 1064 kBChecksum SHA-512
5846d3a66eb3743012b22c534574657b7f1aeb41bae78b9cf3eb11bcc434eed1b97e1e12321e040a658e03536b6069618fc16ca0579ad26603588d6a9c50494b
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Dreimane, Arta
By organisation
Department of Haematology
In the same journal
Leukemia
Hematology

Search outside of DiVA

GoogleGoogle Scholar
Total: 54 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 231 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf